Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 18/20 | 0.55 |
| ▸ | GRIK2 | Q13002 | 18/20 | 0.55 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.52 |
| ▸ | JUN | P05412 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2354695 | 1.00 | GRIK1 (0.55) | GRIK1GRIK2GRIK3JUNNFKB1 | |
| SCHEMBL2354700 | 1.00 | GRIK1 (0.55) | GRIK1GRIK2GRIK3JUNNFKB1 | |
| SCHEMBL3579939 | 0.84 | GRIK1 (0.73) | GRIK1GRIK2GRIK3 | |
| SCHEMBL1865554 | 0.84 | GRIK1 (0.73) | GRIK1GRIK2GRIK3 | |
| SCHEMBL1865552 | 0.84 | GRIK1 (0.73) | GRIK1GRIK2GRIK3 | |
| SCHEMBL3579937 | 0.84 | GRIK1 (0.73) | GRIK1GRIK2GRIK3 | |
| SCHEMBL504608 | 0.84 | GRIK1 (0.73) | GRIK1GRIK2GRIK3 | |
| SCHEMBL8087387 | 0.84 | GRIK1 (0.73) | GRIK1GRIK2GRIK3 | |
| 4-Formylpyridine SCHEMBL25419945 | 0.71 | SLC7A5 (0.54) | NFKB1 | |
| SCHEMBL594002 | 0.71 | GRIK1 (1.00) | GRIK1GRIK2GRIK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611290-B2 | Trypsin-like serine protease inhibitors, and their preparation and use | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2017-04-04 | — | — | US | disclosed |
| EP-2528895-B1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | MEDICINES CO LEIPZIG GMBH (DE) | 2016-03-30 | — | — | EP | disclosed |
| US-20140073573-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2014-03-13 | — | — | US | disclosed |
| US-8598206-B2 | Trypsin-like serine protease inhibitors, and their preparation and use | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2013-12-03 | — | — | US | disclosed |
| EP-2528895-A2 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | The Medicines Company (Leipzig) GmbH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-20110301196-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
| WO-2011094496-A2 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | THE MEDICINES COMPANY (US) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073573-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | SERPINE1, SPINT2, SERPINB1 | GRIK1 2573/4885GRIK2 3351/4885GRIK3 2671/4885 |
| US-20110301196-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | SERPINE1, SPINT2, SERPINB1 | GRIK1 2573/4885GRIK2 3351/4885GRIK3 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.